Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men

27. Oktober 2026 aktualisiert von: Lambda Surgical, Inc

This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.

The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.

LambdaGuide measurements will not be used to guide or modify clinical care.

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.

The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.

Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.

During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.

For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.

Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.

Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.

The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

10

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02111
        • Rekrutierung
        • PINE (Prostate Institution of New England)
        • Kontakt:
        • Hauptermittler:
          • Louis Liou, MD, PhD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

22 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Männlich

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.

Beschreibung

Inclusion Criteria:

  1. Adult male subject (22 years of age or older).
  2. Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
  3. Able and willing to provide informed consent before study participation.
  4. Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
  5. Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
  6. Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.

Exclusion Criteria:

  1. Participation is expected to interfere with or materially delay standard clinical care.
  2. Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
  3. Inability to provide informed consent.
  4. Inability to use the required compatible cystoscope or approved study configuration.
  5. Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: CASE_ONLY
  • Zeitperspektiven: PROSPECTIVE

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinical measurement feasibility
Zeitfenster: Procedure duration

Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained.

Procedure duration
Primary safety endpoint
Zeitfenster: From procedure date to 30 days after (+/-5 days)

Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events.

From procedure date to 30 days after (+/-5 days)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Calibration success
Zeitfenster: During Procedure

Calibration success

During Procedure
Camera deployment and expected image display
Zeitfenster: During Procedure

Camera deployment and expected image display

During Procedure
Spatial capture success
Zeitfenster: During Procedure

Spatial capture success

During Procedure
Valid point-selection success
Zeitfenster: During Procedure

Valid point-selection success

During Procedure
Successful measurement completion
Zeitfenster: During Procedure

Successful measurement completion

During Procedure
Calibration and measurement time
Zeitfenster: During Procedure

Calibration and measurement time (descriptive only)

During Procedure
Procedure interference
Zeitfenster: During Procedure

Procedure interference

During Procedure
User acceptance
Zeitfenster: During Procedure

User acceptance - based on Investigator Questionnaire

During Procedure
Observational comparative measurements (
Zeitfenster: During Procedure

Observational comparative measurements (descriptive only)

During Procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Louis Liou, MD, PhD, PINE - Prostate Institution of New England

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. Oktober 2027

Studienabschluss (Geschätzt)

1. Oktober 2027

Studienanmeldedaten

Zuerst eingereicht

27. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. Oktober 2026

Zuerst gepostet (Tatsächlich)

3. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

27. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • LG-GU-001

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .